Recently a case-control study based on data from the EUROCONDOR trial showed that GFAP-levels were higher at baseline in diabetes patients developing retinal neurodysfunction (as measured by multifocal electroretinography) two years later [7]. This evidence concerns the gene GFAP and diabetes mellitus.